Singapore – March 21, 2025 – Landing Med, a global leader in AI-driven cervical cytology screening, has been awarded first prize for its scientific abstract “Artificial Intelligence Cytological Screening of Cervical Cancer and Subsequent Incidence, Mortality and Healthcare Utilization: A Target Trial Emulation Study among 1.76 Million Women in China” at the prestigious World AI Health Summit in Singapore. In collaboration with Tsinghua University, Peking Union Medical College, Tongji Medical College of Huazhong University of Science and Technology and Nagasaki University, the winning abstract showcased Landing Med’s groundbreaking work in large-scale AI cervical cytology covering more than 1 million women over a five-year period.
The World AI Health Summit, renowned for bringing together the brightest minds in healthcare technology, recognized Landing Med’s abstract for its innovative approach, clinical significance, and real-world impact. The company’s AI-powered cervical cytology project leverages deep learning algorithms to enhance the accuracy, efficiency, and accessibility of cervical cancer screening, particularly in limited-resource settings.
“We are deeply honored to receive this recognition at such a prestigious global event,” said Dr. Xiaorong Sun, Chairwoman of Landing Med. “This award reaffirms our commitment to harnessing AI for improving women’s health. By enabling large-scale, accurate, and cost-effective cervical cancer screening, our technology has the potential to save thousands of lives in underserved regions.”
Landing Med’s AI-driven cytology solution has been deployed across multiple healthcare institutions, demonstrating significant improvements in diagnostic speed and precision. The company’s research and clinical studies have consistently shown that AI-assisted screening can reduce diagnostic errors and enhance early detection rates, thereby facilitating timely and effective treatment.
The World AI Health Summit’s first-prize award serves as a testament to Landing Med’s leadership in the field of AI-driven cervical cytology screening. The company continues to collaborate with global healthcare partners to advance AI applications in pathology, aiming to set new standards in digital diagnostics and preventive healthcare.
CN
